Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHF Research FoundationHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Aug 25 2025 | BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025 Industry News Industry Read More Aug 7 2025 | Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity Industry News Industry Read More Aug 7 2025 | Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System Industry News Industry Read More Jul 14 2025 | Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension Industry News In The News Industry Read More Jul 14 2025 | U.S. FDA Approves KERENDIA® (finerenone) to Treat Patients With Heart Failure With Left Ventricular Ejection Fraction ≥40% Following Priority Review Industry News In The News Industry Read More Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last »
Aug 25 2025 | BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025 Industry News Industry Read More
Aug 7 2025 | Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity Industry News Industry Read More
Aug 7 2025 | Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System Industry News Industry Read More
Jul 14 2025 | Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension Industry News In The News Industry Read More
Jul 14 2025 | U.S. FDA Approves KERENDIA® (finerenone) to Treat Patients With Heart Failure With Left Ventricular Ejection Fraction ≥40% Following Priority Review Industry News In The News Industry Read More
